Pharmaceutical - Johnson & Johnson, Medivir

Filter

Current filters:

Johnson & JohnsonMedivir

Popular Filters

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C

24-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA

25-11-2013

It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

25-10-2013

Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

09-04-2013

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Back to top